Submissions

While DXM is used safely by millions of Americans, some teenagers and young adults are intentionally abusing large quantities of medicines containing DXM in an effort to get high.

CHPA appreciates the opportunity to provide comments to the Food and Drug Administration on the proposed experimental study of qualified health claims about omega-3 fatty acids.

CHPA appreciates the comments of FDA in the February 2006, feedback letter and understands that these comments are FDA’s best advice on designing a protocol to address the safety and efficacy of benzocaine. We have included a revised final protocol for your final review.

Letter from the Consumer Healthcare Products Association, the Food Marketing Institute, the Healthcare Distribution Management Association, and the National Association of Chain Drugstores regarding controlled substances and Lis I chemical registration application fees.

With this letter, the Consumer Healthcare Products Association expresses its great interest in the selection of the industry representative to serve on the Nonprescription Drugs Advisory Committee.

CHPA sees no need for the agency to initiate a rulemaking on this matter. Sufficient precedent already exists for an active drug ingredient to be simultaneously marketed in both prescription and OTC drug products based on narrow distinctions.

The following comments are submitted by the Joint Oral Care Task Group CHPA and the Cosmetic, Toiletry, and Fragrance Association with respect to the Draft Guidance for Industry on Gingivitis: Development and Evaluation of Drugs for Treatment or Prevention.

CHPA is deeply concerned that safe and effective medicines manufactured by its member companies are being diverted to manufacture meth. We understand the scope of this problem and are committed to the need for strong action to prevent the diversion of these important medicines to the illegal manufacturing of methamphetamine.

CHPA has supported and continues to support the timely provision of complete and accurate product information to healthcare professionals and patients in an easily accessible format, and commends the Agency for considering new approaches to disseminating emerging drug safety-related data.